French Bulldog Degenerative Myelopathy (DM): What the DNA Test Actually Shows - and Why 'At Risk' Doesn't Mean What You Think

You are holding a health certificate. Under the genetic results, it says: DM: AT RISK (A/A). The breeder mentioned it briefly and moved on. You typed it into a search engine and found articles about German Shepherds going paralyzed. Now you are deciding whether to walk away from a puppy you already love.

That result deserves a clear explanation - not a reassurance, but actual context. Here is what the science shows, what the absence of confirmed French Bulldog cases means, and why the conditions you should actually worry about are different ones entirely.

What Degenerative Myelopathy Actually Is

Canine degenerative myelopathy is a progressive spinal cord disease. It attacks the white matter - the insulating sheaths that carry signals between the brain and the limbs. As those pathways break down, coordination fails. Strength goes. Full paralysis follows.

The disease is associated with a mutation in the SOD1 gene - specifically the SOD1:c.118G>A variant. SOD1 stands for superoxide dismutase 1, and this is the same gene implicated in familial ALS, the human motor neuron disease. The parallel is real, and it explains why the DM mutation is taken seriously in the breeds where it has been confirmed.

How DM Progresses in Confirmed Breeds

In German Shepherds and Corgis - the breeds with the best-documented DM history - the clinical course follows a predictable pattern:

• Hind-limb ataxia: stumbling, dragging paws, difficulty placing feet correctly
• Progressive weakness in the rear legs, then loss of voluntary movement
• Full paralysis of the hindquarters, with loss of bladder and bowel control
• Eventually, forelimb weakness and respiratory compromise in advanced stages

From first noticeable hind-leg wobbling to non-ambulatory rear paralysis, German Shepherds typically take six to twelve months on average. The full disease course can extend to three years or beyond, depending on the level of supportive care provided. Physical rehabilitation - structured exercises three to five times daily plus separate daily hydrotherapy sessions - is the only intervention shown to meaningfully slow progression. One study found that dogs receiving intensive daily rehab remained ambulatory significantly longer than those receiving moderate or no rehabilitation.

Critically, even in confirmed DM breeds, the SOD1 mutation has incomplete penetrance. Some dogs test A/A and never develop clinical signs during their lifetime. The mutation is necessary but not sufficient to cause disease. Additional co-factors appear required; a modifier gene (SP110) has been identified in Pembroke Welsh Corgis that influences disease risk and onset age, but for most affected breeds the full co-factor picture remains unknown.

Why DM Appears on French Bulldog DNA Reports at All

Genetic testing companies detected the SOD1:c.118G>A mutation in French Bulldogs and, following the same logic used for German Shepherds, added the breed to their DM panels. The mutation is genuinely present. Worldwide testing data shows 2 to 5 percent of French Bulldogs test homozygous A/A, and 18 to 33 percent test heterozygous G/A.

An Italian population study (PMC11429382) produced similar numbers: 6.77 percent A/A, 30.83 percent G/A, and 62.40 percent N/N. Whatever the precise rate across populations, a substantial share of Frenchies carry one or two copies of the mutation.

The 4-panel test - the genetic screening widely marketed to Frenchie buyers - screens for four conditions: DM, CMR1 (canine multifocal retinopathy 1), JHC (juvenile hereditary cataracts), and HUU (hyperuricosuria). The test exists because all four mutations are present in the breed. Whether all four are clinically relevant is a different question entirely.

The Fact Most Pages Do Not Tell You

Definitive diagnosis of degenerative myelopathy requires histopathological examination of spinal cord tissue - meaning post-mortem analysis under a microscope. Clinical signs alone cannot confirm DM; they can only suggest it. This distinction matters enormously for how to interpret any test result.

DM has never been histopathologically confirmed in a purebred French Bulldog. Not one case. Despite the SOD1 mutation appearing in the breed at meaningful rates, the confirmed spinal cord pathology that defines DM as a disease has never been documented in a purebred Frenchie.

The closest the literature has come is a 2026 case report by Chan et al. in the Journal of Small Animal Practice. That paper documented DM in a Boston Terrier-French Bulldog mixed-breed dog - the first adjacent-breed case in the literature. It involves a cross, not a purebred French Bulldog, and it remains a single case. It is relevant to researchers tracking where this disease may eventually appear; it is not evidence that DM is a clinical threat to purebred Frenchies today.

Dr. Jerold Bell, a veterinary geneticist at Tufts University and OFA Board member, has stated directly that DM is not a relevant clinical marker for French Bulldogs, citing the breed's absence from confirmed case records. The French Bulldog Club of America's CHIC program reflects this position: CHIC for French Bulldogs requires hip evaluation, patella evaluation, cardiac evaluation, and CAER/OFA eye certification. DM is not among the four required tests.

The SOD1 mutation is present in French Bulldogs, but the co-factors required to trigger clinical degenerative myelopathy appear to be absent in the breed. No histopathologically confirmed case has ever been documented in a purebred French Bulldog.

An Australian French Bulldog community petition formally requested removal of DM from breed-specific genetic testing panels, citing the absence of confirmed cases and the buyer confusion the result creates. That petition exists because the scenario described in the opening paragraph of this article happens constantly.

How to Read a Frenchie DM Result

The three possible results on an SOD1 DM test, and what each actually means in a French Bulldog context:

• N/N (normal/clear): Two normal copies of the SOD1 gene. In confirmed DM breeds, this is the lowest-risk genotype. In French Bulldogs, the distinction between N/N and A/A has not translated into any observed difference in clinical outcomes, because DM-like disease has not been observed in the breed.
• G/A (carrier): One normal copy and one mutated copy. In confirmed DM breeds, carriers rarely develop disease themselves but can pass the mutation to offspring. In French Bulldogs, this result has no documented health consequence for the dog carrying it.
• A/A (at risk): Two mutated copies. In confirmed DM breeds, this genotype is associated with elevated disease risk - though incomplete penetrance means not all A/A dogs ever develop signs. In French Bulldogs, this result has never been associated with a confirmed case of DM.

Embark Vet's own SOD1A result page notes that for certain breeds, the clinical significance of the mutation is unclear and breeding decisions should not be made solely on this result. That caveat appears on the result page for a reason.

The 4-Panel Test Decoded

The 4-panel test covers four hereditary conditions. Here is how they compare on what actually matters to a French Bulldog buyer:

Condition	What It Affects	Confirmed in Purebred Frenchies?	How to Interpret an Affected Result
DM (degenerative myelopathy)	Spinal cord and mobility	No - no histopathologically confirmed cases	Mutation present; clinical risk currently considered minimal for the breed
CMR1 (canine multifocal retinopathy 1)	Retinal lesions; vision is usually not significantly affected	Yes - confirmed clinical cases in breed	Affected dogs may develop retinal lesions; genuinely worth factoring into breeding
JHC (juvenile hereditary cataracts)	Lens opacity and vision	Yes - confirmed in breed	Higher risk of early-onset cataracts; a real and relevant finding
HUU (hyperuricosuria)	Uric acid metabolism and urinary tract	Yes - confirmed in breed	Elevated uric acid excretion can lead to urate bladder or kidney stones

Three of the four conditions on this panel have direct, documented clinical significance for French Bulldogs. DM currently does not. This does not make the DM result worthless - population data has research value, and the picture may change if confirmed cases emerge - but it does change how a buyer should weight it when evaluating a puppy.

What to Ask a Breeder - and Red Flags to Watch For

A breeder who understands French Bulldog genetics will not use "DM clear" as a primary selling point without explaining what the result does and does not mean for the breed.

Questions Worth Asking

• Does the breeding pair have CHIC numbers? This confirms completion of the four breed-required health tests - note that DM is not among them.
• Have the parents been OFA-evaluated for hips, patellas, and cardiac health?
• Can you explain what the DM result means specifically for French Bulldogs, not just dogs in general?
• What is the spine and disc history of the parents and any older siblings from previous litters?

Red Flags in How DM Results Get Presented

• Advertising "DM clear" as a headline health credential while lacking OFA structural clearances
• Presenting an N/N DM result as evidence of superior spinal health without any spine-specific imaging history
• No mention of CHIC requirements alongside the genetic panel
• Claiming that an A/A parent should be excluded from breeding based solely on the DM result

A breeder who dismisses DM entirely without explanation is not ideal. Neither is a breeder who uses it as a fear-based marketing term. The honest answer sits between those positions: the mutation is present, it is worth tracking at the population level, and it currently has no confirmed clinical significance in purebred French Bulldogs.

What Does Matter for Frenchie Spinal Health

While DM occupies discussion space it has not earned, two conditions with solid clinical documentation in the breed receive less buyer attention than they deserve.

IVDD: Intervertebral Disc Disease

IVDD is the most common neurological diagnosis in French Bulldogs, accounting for 45.5 percent of neurological cases in the breed. The French Bulldog is a chondrodystrophic breed - its cartilage and disc structure make herniation a genuine, recurring risk throughout the dog's life. A disc can rupture acutely, driving nuclear material into the spinal canal and causing sudden hindlimb weakness, pain, or paralysis. This is not a theoretical risk. It happens in the breed regularly, across all age groups.

IVDD can be evaluated during the dog's lifetime through MRI. Some breeders conduct spinal imaging on breeding stock. When reviewing a breeder's health documentation, ask specifically about IVDD history in the lines - not just about what the genetic panel shows.

Hemivertebrae

Hemivertebrae are malformed vertebrae - wedge-shaped rather than rectangular - that result from the same developmental pathway that gives French Bulldogs their characteristic screw tail. Most are asymptomatic. When they occur in the thoracic spine in certain configurations, they can cause spinal cord compression and produce progressive neurological signs. Screening requires spinal imaging and is not captured by any genetic panel test currently available. It is a structural problem, not a mutation problem.

If Your Frenchie Shows Hind-Leg Weakness

Stumbling, dragging a rear foot, reluctance to jump, or sudden collapse in the hindquarters are symptoms shared by several conditions. Because DM cannot be confirmed ante-mortem and its early presentation is indistinguishable from IVDD, the diagnostic process should follow a clear order:

1. Contact a veterinarian the same day. Do not wait to see if the symptom resolves - early-stage IVDD is more treatable before significant spinal cord compression occurs.
2. Request a full neurological examination to localize the lesion and assess severity.
3. Pursue MRI or CT imaging to identify disc herniation, hemivertebrae compression, or other structural causes. These are far more likely in a French Bulldog than DM.
4. Rule out IVDD, hemivertebrae-associated compression, and other confirmed spinal conditions before DM appears anywhere on the differential diagnosis list.
5. If structural causes are ruled out and signs continue to progress over months without explanation, discuss with a veterinary neurologist whether DM warrants consideration - acknowledging that ante-mortem confirmation is not possible for any dog.

What Would Need to Change Before DM Becomes a Genuine Concern

Science updates when evidence accumulates. The current picture could shift if any of the following emerge from the research literature:

• A histopathologically confirmed DM case in a purebred French Bulldog, documented in a peer-reviewed journal with full post-mortem spinal cord analysis
• Multiple confirmed cases allowing researchers to characterize breed-specific clinical presentation and progression patterns
• Identification of the co-factors that, combined with the SOD1 mutation, trigger clinical disease - which could reveal whether French Bulldogs carry or lack those factors
• Prospective longitudinal studies tracking A/A French Bulldogs across their lifetimes to document actual clinical outcomes

The 2026 Chan et al. mixed-breed case is exactly the kind of data point that moves this question forward. One case in a cross does not confirm DM risk in purebreds, but it does signal that researchers are right to keep watching. If confirmed purebred cases appear, the guidance in this article would need revision. Until they do, the current evidence does not support treating a Frenchie's DM test result as a meaningful clinical risk.

Frequently Asked Questions

Does 'DM: At Risk (A/A)' on a French Bulldog health certificate mean the dog will develop paralysis?

No. It means the dog carries two copies of the SOD1 mutation associated with degenerative myelopathy in other breeds. DM has never been histopathologically confirmed in a purebred French Bulldog, so this result cannot be linked to a confirmed clinical risk in the breed. The mutation is real; the confirmed disease has not materialized in the purebred French Bulldog population.

Should I avoid buying a puppy whose parent tested A/A for DM?

The French Bulldog Club of America's CHIC program does not require DM testing, and OFA guidance acknowledges the result lacks confirmed clinical relevance for the breed. An A/A result alone is not a valid reason to pass on an otherwise health-tested puppy. Focus instead on whether the breeding pair completed CHIC requirements: hips, patellas, cardiac, and eye evaluations - those are the clearances that reflect genuine investment in breed health.

What is the difference between DM and IVDD in French Bulldogs?

IVDD is a confirmed and common spinal condition in Frenchies, accounting for nearly half of all neurological diagnoses in the breed. It involves disc material herniating into the spinal canal and can cause sudden, severe symptoms. DM is a progressive spinal cord degeneration that has never been confirmed in a purebred Frenchie. If a French Bulldog shows hind-leg weakness, IVDD should be the first condition investigated - not DM.

Why do genetic testing companies still include DM for French Bulldogs if the disease has not been confirmed in the breed?

The SOD1 mutation genuinely exists in French Bulldogs at measurable rates, and testing companies typically panel breeds where the mutation is present. Embark Vet's own result page notes that the clinical significance is unclear for certain breeds and that breeding decisions should not rest on this result alone. The inclusion has legitimate research value - tracking the mutation over time allows scientists to identify whether confirmed cases eventually emerge.

Can a French Bulldog with the DM mutation be treated if it does develop neurological signs?

If a French Bulldog develops hind-leg weakness, the first priority is diagnosing the actual cause - which in this breed is far more likely to be IVDD or hemivertebrae compression than DM. For confirmed DM in breeds where it is documented, physical rehabilitation is the only intervention shown to extend ambulatory life; there is no disease-modifying drug treatment for DM in any species. Treatment options depend entirely on a confirmed diagnosis, which requires ruling out every more-likely condition first.

How do I know whether a breeder's genetic health testing is thorough versus a marketing display?

Ask whether the breeding pair has CHIC numbers, which requires completing all four breed-mandated evaluations - hips, patellas, cardiac, and eyes - none of which are genetic panel tests. A breeder presenting DM clearance as a headline health credential while lacking OFA structural clearances is showing you the less important document first. The 4-panel genetic test is inexpensive and easy to run; the OFA structural evaluations take more effort and reflect a more serious commitment to the breeding program.